Ventyx Biosciences, INC 8-K filings

Ventyx Biosciences, Inc. has completed its merger with Eli Lilly and Company, becoming a wholly-owned subsidiary.

Ventyx Biosciences, Inc. stockholders have approved the Agreement and Plan of Merger with Eli Lilly and Company, paving the way for Ventyx to become a wholly owned subsidiary.

Ventyx Biosciences provides supplemental disclosures on its pending $14.00 per share cash merger with Eli Lilly, including financial analyses, partnership projections, and new stockholder lawsuits.

Ventyx Biosciences' Board approved cash bonus awards for key executives in lieu of equity grants, tied to the anticipated merger with Eli Lilly and Company.

Eli Lilly and Company will acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company, for approximately $1.2 billion in an all-cash transaction.

Ventyx Biosciences announced its third quarter 2025 financial results and highlighted positive Phase 2 data for its NLRP3 inhibitor VTX3232 in cardiovascular risk factors and Parkinson's disease.

Ventyx Biosciences announced positive topline results from its Phase 2 study of VTX3232, demonstrating significant reductions in cardiovascular risk factors and good tolerability.

Ventyx Biosciences announced its second quarter 2025 financial results, highlighting positive Phase 2a Parkinson's data and progress across its clinical pipeline, with cash sufficient to fund operations into at least H2 2026.

Ventyx Biosciences announced positive top-line results from its Phase 2a safety and biomarker trial of VTX3232 in early-stage Parkinson's disease, demonstrating safety, target engagement, and promising clinical signals.

VENTYX Biosciences, Inc. announced the results of its Annual Meeting of Stockholders held on June 4, 2025, confirming the re-election of two Class I directors, the advisory approval of executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm.

Ventyx Biosciences announces its first quarter 2025 financial results, highlighting progress in its clinical pipeline and a cash balance sufficient to fund operations into at least H2 2026.

Ventyx Biosciences announces its fourth quarter and full year 2024 financial results, highlighting progress in its clinical pipeline and a strong cash position to fund operations into at least H2 2026.

Ventyx Biosciences announces clinical trial updates for its NLRP3 inhibitor portfolio and highlights its 2025 pipeline strategy, with multiple Phase 2 data readouts expected.

Ventyx Biosciences reported its third quarter 2024 financial results, highlighted progress in its clinical pipeline, and announced key upcoming trial initiations.

Ventyx Biosciences has entered into a securities purchase agreement with Aventis Inc. for a $27 million private placement of Series A Non-Voting Convertible Preferred Stock.

Ventyx Biosciences has appointed Roy M. Gonzales as interim principal financial officer and interim principal accounting officer, effective August 30, 2024, following the departure of Martin D. Auster.

Ventyx Biosciences reported its second quarter 2024 financial results, highlighting progress in its clinical pipeline and the appointment of a new Chief Medical Officer.

Ventyx Biosciences held its annual meeting on June 5, 2024, where shareholders re-elected two Class III directors, approved executive compensation on an advisory basis, and ratified the appointment of Ernst & Young LLP as the independent auditor.

Ventyx Biosciences reported positive preclinical results for its drug candidate VTX3232, demonstrating significant improvements in obesity and related health markers in mouse models.

Ventyx Biosciences has appointed Matthew Moore as its new Chief Operating Officer, effective May 16, 2024.

Ventyx Biosciences reported its first quarter 2024 financial results, highlighting progress in its clinical pipeline and a strong cash position to fund operations into at least the second half of 2026.

Ventyx Biosciences' Chief Business Officer, Christopher Krueger, has resigned effective April 15, 2024, and will transition into a consulting role with the company.

Ventyx Biosciences reported positive clinical data for its NLRP3 inhibitor portfolio and updated its pipeline, extending its cash runway into at least the second half of 2026.

Ventyx Biosciences has entered into a stock purchase agreement for a $100 million private placement to fund clinical development and extend its cash runway into at least the second half of 2026.

Ventyx Biosciences announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and a cash runway into at least the second half of 2025.